Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations

Trial Profile

A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms HOVON 141 CLL/ VIsion
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Jun 2018 Enrollment in the trial is ongoing, 62 of 207 planned patients has been enrolled, as reported in an abstract presented at the 23rd Congress of the European Haematology Association. The DSMB recommends continuing of the study.
    • 17 Jun 2018 Results of an Interim Analysis presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top